Kabimustine

Bendamustine

Features

Bendamustine is a bifunctional mechlorethamine derivative containing a purinelike benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.

Dosage

Dosing Instructions for CLL

Recommended Dosage:

The recommended dose is 100 mg/m2 administered intravenously over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.

Dosing Instructions for NHL

Recommended Dosage:

The recommended dose is 120 mg/m2 administered intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles.

Indications

Chronic Lymphocytic Leukemia (CLL)

Benamustine is indicated for the treatment of patients with chronic lymphocytic leukemia.

Non-Hodgkin Lymphoma (NHL)

Benamustine is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Product Information

Type I amber glass vials of 50 ml with rubber stopper and an aluminium flip-off cap.

50 ml-vials contain 100 mg bendamustine hydrochloride and are supplied in packs of 1 and 5 vials.

 

For the use of an Oncologist / a Hospital / a Cancer Institute